Anteris Technologies Global Corp. (NASDAQ:AVR – Get Free Report) Director Susan Elizabeth Knight purchased 11,000 shares of the company’s stock in a transaction dated Tuesday, June 2nd. The shares were purchased at an average cost of $9.29 per share, for a total transaction of $102,190.00. Following the transaction, the director directly owned 11,000 shares in the company, valued at approximately $102,190. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.
Anteris Technologies Global Price Performance
Shares of NASDAQ AVR opened at $9.65 on Friday. Anteris Technologies Global Corp. has a one year low of $2.85 and a one year high of $10.14. The business’s fifty day moving average price is $6.74 and its 200-day moving average price is $5.83. The stock has a market capitalization of $939.33 million, a PE ratio of -4.33 and a beta of 1.78.
Anteris Technologies Global (NASDAQ:AVR – Get Free Report) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.01). Anteris Technologies Global had a negative net margin of 5,148.78% and a negative return on equity of 124.76%. The firm had revenue of $0.49 million for the quarter, compared to analysts’ expectations of $0.77 million. During the same period in the prior year, the company earned ($0.61) EPS. As a group, equities analysts expect that Anteris Technologies Global Corp. will post -1.14 EPS for the current fiscal year.
Institutional Investors Weigh In On Anteris Technologies Global
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on AVR. Wells Fargo & Company began coverage on Anteris Technologies Global in a research report on Wednesday, March 11th. They set an “overweight” rating and a $16.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $15.00 price objective on shares of Anteris Technologies Global in a research note on Friday, March 27th. Barclays increased their price objective on Anteris Technologies Global from $17.00 to $18.00 and gave the stock an “overweight” rating in a report on Friday, May 15th. Wall Street Zen upgraded Anteris Technologies Global from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Anteris Technologies Global in a research report on Friday, May 29th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $16.00.
Get Our Latest Stock Report on AVR
About Anteris Technologies Global
Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.
Further Reading
- Five stocks we like better than Anteris Technologies Global
- Macy’s Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious
- NVIDIA Sends a Message With RTX Spark—This Is What It Says
- Buy the Dip? Broadcom’s AI Moat Is Wider Than Ever
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
Receive News & Ratings for Anteris Technologies Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anteris Technologies Global and related companies with MarketBeat.com's FREE daily email newsletter.
